# Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

> **NCT05559905** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 116 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **DRUG:** Molnupiravir
- **DRUG:** Placebo
- **BIOLOGICAL:** RSV A Memphis 37b

## Key facts

- **NCT ID:** NCT05559905
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-02
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-06-08
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559905, "Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05559905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*